Smith & Nephew LSE: SN; NYSE: SNN sprzęt medyczny m.in. protezy
Smith & Nephew LSE: SN; NYSE: SNN sprzęt medyczny m.in. protezy
wykres LSE
http://finance.yahoo.com/echarts?s=sn.l+Interactive
https://stockcharts.com/h-sc/ui?s=SN.L
https://www.investing.com/equities/smith-and-nephew
wykres NYSE
http://finance.yahoo.com/echarts?s=snn+Interactive
https://stockcharts.com/h-sc/ui?s=SNN
Smith & Nephew LSE: SN; NYSE: SNN sprzęt medyczny
http://en.wikipedia.org/wiki/Smith_%26_Nephew
https://www.smith-nephew.com/
wątek o spółce
http://thelion.com/bin/aio_msg.cgi?cmd= ... symbol=snn
dywidendy
https://www.investing.com/equities/smit ... -dividends UK
https://www.investing.com/equities/smit ... -dividends USA
Ostatnio zmieniony 15 kwie 2023 15:01 przez slayer74, łącznie zmieniany 3 razy.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
REKLAMA
Re: Smith & Nephew LSE: SN; NYSE: SNN sprzęt medyczny
Smith & Nephew Stock Is Trading Lower Despite Posting Surge In Q2 Revenues, Profit
Smith & Nephew Plc
SNN 0.07%
revenues soared in Q2 as COVID-19 restrictions eased and levels of elective surgery returned towards normal in many markets.
The Company reported revenues of $1.3 billion, up 48.2%, with underlying growth of 40.3%.
Compared to Q2 2019, Q2 2021 revenue was down -1.0% on an underlying basis, primarily due to the Orthopedics unit that slipped 6.2%.
All three franchises delivered strong revenue growth, with Orthopedics up 43.4% (53.0% reported), Sports Medicine & ENT up 50.9% (58.5% reported) and Advanced Wound Management up 27.2% (33.5% reported).
SNN swung to a pretax profit for the first half of the year as revenue rose. It posted a profit of $223 million compared with a pretax loss of $34 million a year ago. First-half trading profit rose to $459 million from $172 million the year before.
Outlook: Smith & Nephew said it was on track to meet its full-year guidance of underlying revenue growth between 10%-13%, as it has started to re-capture its pre-covid momentum, assuming that the pandemic does not constrain surgery volumes in the second half of 2021.
The Company expects a trading profit margin of 18.0% to 19.0%.
Price Action: SNN shares are down 7.39% at $40.56 during the premarket session on the last check Thursday.
https://www.benzinga.com/news/earnings/ ... ues-profit
Smith & Nephew Plc
SNN 0.07%
revenues soared in Q2 as COVID-19 restrictions eased and levels of elective surgery returned towards normal in many markets.
The Company reported revenues of $1.3 billion, up 48.2%, with underlying growth of 40.3%.
Compared to Q2 2019, Q2 2021 revenue was down -1.0% on an underlying basis, primarily due to the Orthopedics unit that slipped 6.2%.
All three franchises delivered strong revenue growth, with Orthopedics up 43.4% (53.0% reported), Sports Medicine & ENT up 50.9% (58.5% reported) and Advanced Wound Management up 27.2% (33.5% reported).
SNN swung to a pretax profit for the first half of the year as revenue rose. It posted a profit of $223 million compared with a pretax loss of $34 million a year ago. First-half trading profit rose to $459 million from $172 million the year before.
Outlook: Smith & Nephew said it was on track to meet its full-year guidance of underlying revenue growth between 10%-13%, as it has started to re-capture its pre-covid momentum, assuming that the pandemic does not constrain surgery volumes in the second half of 2021.
The Company expects a trading profit margin of 18.0% to 19.0%.
Price Action: SNN shares are down 7.39% at $40.56 during the premarket session on the last check Thursday.
https://www.benzinga.com/news/earnings/ ... ues-profit
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Smith & Nephew LSE: SN; NYSE: SNN sprzęt medyczny m.in. protezy
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Smith & Nephew LSE: SN; NYSE: SNN sprzęt medyczny m.in. protezy
Smith & Nephew also weakened by 1.1% following a downgrade to 'underweight' from 'overweight' at Barclays, which predicted further share losses in orthopaedics.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Smith & Nephew LSE: SN; NYSE: SNN sprzęt medyczny m.in. protezy
Smith & Nephew (LON:SN) (NYSE:SNN) is Bernstein's top pick in EU medtech, analysts told investors in a note Friday.
The analysts, who have an Outperform rating and a $36 price target on the stock, stated that the "ten-year turnaround is finally ready to deliver" and that the firm likes SNN's team of CEO Deepak Nath and CFO Anne-Francoise Nesmes. They also noted the work done by the company under former CEOs in previous years.
According to Bernstein, the gaps in SNN's portfolio are now filled, driving an acceleration in sales growth.
"S&N's historic underperformance in Ortho has been largely driven by gaps in the portfolio over time (revision hip, uni knee, cementless knee, large trauma plates). With a full suite of products now in place, S&N should grow at or above the market in the Ortho segments where it has lagged," the analysts wrote.
The "12-point plan will drive top-line growth and margin improvement," said the analysts, adding that expectations have bottomed out.
"The specificity of the initiatives laid out by Mr. Nath give us confidence in the path to strong earnings growth," they added.
"At Q4, the mid-term margin target was reduced, while the stock went up +4%. We are above the new guidance of 20% by 2025 (at 21.1%) while consensus is at 19.1%."
The analysts, who have an Outperform rating and a $36 price target on the stock, stated that the "ten-year turnaround is finally ready to deliver" and that the firm likes SNN's team of CEO Deepak Nath and CFO Anne-Francoise Nesmes. They also noted the work done by the company under former CEOs in previous years.
According to Bernstein, the gaps in SNN's portfolio are now filled, driving an acceleration in sales growth.
"S&N's historic underperformance in Ortho has been largely driven by gaps in the portfolio over time (revision hip, uni knee, cementless knee, large trauma plates). With a full suite of products now in place, S&N should grow at or above the market in the Ortho segments where it has lagged," the analysts wrote.
The "12-point plan will drive top-line growth and margin improvement," said the analysts, adding that expectations have bottomed out.
"The specificity of the initiatives laid out by Mr. Nath give us confidence in the path to strong earnings growth," they added.
"At Q4, the mid-term margin target was reduced, while the stock went up +4%. We are above the new guidance of 20% by 2025 (at 21.1%) while consensus is at 19.1%."
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
REKLAMA
Kto jest online
Użytkownicy przeglądający to forum: Obecnie na forum nie ma żadnego zarejestrowanego użytkownika i 16 gości